Latest news with #Testing
The Irish Sun
2 days ago
- Automotive
- The Irish Sun
F1 team forced to release statement after star rushed to medical centre after suffering horror crash in modified car
The driver was assessed after the incident TESTING CRASH F1 team forced to release statement after star rushed to medical centre after suffering horror crash in modified car ALPINE have issued a statement after driver Franco Colapinto was involved in a crash during testing. Images appeared to show that Colapinto had collided with barriers at Hungaroring during Pirelli tyre testing. 3 Franco Colapinto has been involved in a crash during Pirelli tyre testing Credit: Shutterstock Editorial 3 Alpine have released a statement following what looked like a bad crash at Hungaroring Credit: X Alpine is one of a number of Formula One teams that are currently testing for the 2026 campaign during the F1 summer break. Teams have reportedly used modified cars to help Pirelli simulate the loads that the 2026 regulations are due to generate in the short summer break before the 2025 schedule continues in the Netherlands at the end of the month. 2026 tyres are set to be 25mm narrower at the front and 30mm narrower at the rear. Colapinto, Lando Norris, Liam Lawson and Paul Aron are some of the names that have been testing this week. READ MORE IN F1 'BEAUTIFUL' Lando Norris' girlfriend Margarida Corceiro shows off sideboob in risque outfit But things went awry for Colapinto when he crashed on turn 11 during a lap around Hungaroring. A team statement from Alpine said: "Team Update. During Day 2 of Pirelli Tyre Testing at the Hungaroring this morning, Franco Colapinto had an incident at Turn 11. "Franco was assessed on site at the medical centre and is OK." It comes after a frustrating outing for Colapinto at last week's Hungary Grand Prix. CASINO SPECIAL - BEST CASINO BONUSES FROM £10 DEPOSITS The 22-year-old Argentine finished in 18th place, one place in front of teammate Pierre Gasly. Colapinto is in his first year with Alpine after replacing Jack Doohan behind the wheel. Toto Wolff defends F1 driver Lewis Hamilton after 'useless' comments The former Williams driver is yet to score a point since replacing Doohan. F1 will return on August 31 with the Dutch Grand Prix at the Circuit Zandvoort.
Yahoo
02-07-2025
- Business
- Yahoo
Odyssey Investment Partners to Sell Applied Technical Services to SGS for $1.325 Billion
NEW YORK, July 02, 2025--(BUSINESS WIRE)--Odyssey Investment Partners, LLC ("Odyssey") announced today that it has entered into a definitive agreement to sell its portfolio company Applied Technical Services, Inc. ("ATS" or the "Company"), a leading provider of specialized Testing, Inspection, Calibration and Forensic Consulting solutions in North America, to SGS, the world's leading Testing, Inspection and Certification company, in a transaction valued at $1.325 billion. ATS has a nearly 60-year history of providing critical solutions to clients across a diverse set of large and stable end markets including manufacturing, power generation, food and beverage, chemicals, aerospace, life sciences, and defense. Its market-leading service offerings include materials testing, environmental simulation, chemical analysis, calibration, non-destructive inspection, and forensic consulting. ATS is headquartered in Marietta, Georgia and employs approximately 2,100 team members in over 85 locations across the United States. ATS has undergone a dramatic transformation since it was acquired by an Odyssey fund in 2020. During this time, the Company completed nearly 40 acquisitions, through which it added considerable scale and diversified its service offerings and end markets. Further, Odyssey constructed a world-class executive team that has driven the Company forward and built out a centralized corporate structure that has enhanced efficiency across ATS's footprint. Jonathan Place, a Managing Principal at Odyssey, said, "We are very proud of our highly successful investment in ATS. In partnership with the management team, we have built an unparalleled North American business in terms of scale and diversity, and one that is regarded by its customers as a best-in-class service provider. As a result of our many accomplishments, ATS is well positioned for continued long-term growth and strong performance, and has attracted the interest of the global leader, which envisions it as a critical piece in achieving its considerable ambitions in North America. In addition, the strength and size of the SGS network will provide greater opportunities for ATS to expand its services to new geographies. We are grateful to the management team for their hard work and dedication and wish all of ATS's employees continued success as part of SGS." ATS CEO Mike McIlwain added, "Odyssey has been an exceptional partner to ATS over the past four years. Under its ownership, our business achieved unprecedented growth as a result of the team's vision, industry experience, and the considerable financial and strategic resources they made available to us. I want to thank the entire ATS team for their tireless efforts and commitment to realizing this vision. Together with Odyssey, we've built upon our strong brand and service culture, which has further strengthened our loyal customer relationships. As we move on to a new chapter, we thank Odyssey for our collaboration, the benefits of which will be felt for years to come." Completion of the transaction, which is expected by the end of 2025, is subject to customary closing conditions. Houlihan Lokey is serving as lead financial advisor with Rothschild & Co. as co-financial advisor, and Latham & Watkins LLP is serving as legal counsel to Odyssey. About Odyssey Investment Partners Odyssey Investment Partners is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers and using its buy, build and integrate approach to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes primarily majority-controlled investments in industrial and business services sectors with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit View source version on Contacts Mark Semer / Grace CartwrightGasthalter & Co.(212) 257-4170odyssey@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
18-06-2025
- Business
- National Post
28 Strategy Execution and Evolves its Executive Committee
Article content PARIS — , a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers' excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness. Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People – and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product Lines, enabling global offers development, unlocking greater cross-selling opportunities, and driving growth and profitability. Article content The current six operating geographical Regions will be reorganized into four greater Regions: Americas, Europe, Asia Pacific, Middle East Caspian & Africa. The Product lines will be managed under three executive committee members who will lead: Industrials and Commodities, Urbanization and Assurance, and Consumer Products Services. These groupings at the executive committee level are aligned with customer workflows and market needs. Article content Article content Considering the company ambition to scale performance programs across all the Regions and Product lines, a Chief Performance Officer and Executive Committee member role will be dedicated to lead the LEAP I 28 performance pillar and the overall optimization of key performance functions of operational excellence & performance, and sales & marketing. This role will drive the design, governance, and overall implementation and monitoring of these programs in coordination with other stakeholders across the organization. Article content 'By directly connecting Product Lines to a simplified regional structure, we are strengthening our regional expertise and building deeper relations with our customers. This organization will also allow us to create more agility as we accelerate the execution of our LEAP | 28 strategy. Article content This new organization will leverage scale, benefit from a well-defined structure, thus speeding up decision making, performance impact, and innovation. I fully trust our Bureau Veritas Executive team to mobilize the entire organization to achieve our vision and deliver on our ambition.' Article content The transition period will extend from July 1 st to the end of August 2025. Effective September 1 st 2025, the Group Executive Committee will be structured and composed as follows: Article content Product Lines: Article content Industrials and Commodities: Executive Vice-President > Matthieu Gondallier De Tugny Urbanization and Assurance: Executive Vice-President > Marc Roussel Consumer Products Services: Executive Vice-President > Catherine Chen Article content Business Functions: Article content Corporate development & sustainability: Executive Vice-President > Juliano Cardoso Chief Performance Officer: Executive Vice-President > Laurent Louail Chief Digital & Innovation Officer: Executive Vice-President DxT (Digital & Technology) > Philipp Karmires Article content Support Functions: Article content *** Article content About Bureau Veritas Article content Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. Article content *** Article content Biographies: Article content Vincent Bourdil, Article content appointed Executive Vice-President, Europe, joined Bureau Veritas in 2016 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Global Business Lines & Performance before becoming Executive Vice-President, Commodities, Industry & Facilities, Southwest Europe. Article content Khurram Majeed Article content remains Executive Vice-President, Middle East, Caspian & Africa. He is a seasoned industry leader with over 23 years of senior management experience across energy, oil & gas, and other sectors. Khurram joined Bureau Veritas in 2024 as Executive Vice-President, Middle East, Caspian & Africa. Article content Surachet Tanwongswal Article content remains Executive Vice-President Asia Pacific. He joined Bureau Veritas in 2024 as Executive Vice-President for Commodities, Industry & Facilities in Asia Pacific. Prior to this, Surachet held leadership roles at Ecolab and other global B2B companies. Article content Matthieu Gondallier de Tugny, Article content appointed Executive Vice-President Industrials and Commodities, joined Bureau Veritas in 1994 and has held various technical, operational, and leadership roles in Marine & Offshore. His most recent role was Executive Vice-President, Marine & Offshore. Article content Marc Roussel, Article content appointed Executive Vice-President Urbanization and Assurance, joined Bureau Veritas in 2015 and has held multiple leadership roles across the company. His most recent role was Executive Vice-president, Commodities, Industry & Facilities, France. Article content Catherine Chen Article content remains Article content Article content Executive Vice-President Consumer Products Services. She joined Bureau Veritas in 2005 and has held various sales, marketing, and operational leadership roles in Consumer Product Services. Catherine will continue to connect Consumer Products & Technology Product Lines, as Executive Vice-President, Consumer Products Services. Article content Laurent Louail, Article content appointed Executive Vice-President Chief Performance Officer, joined Bureau Veritas in 1995 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Commodities, Industry & Facilities in Southwest Europe, before becoming Executive Vice-President, Global Business Lines & Performance. Article content Juliano Cardoso Article content remains Executive Vice-President Corporate Development & Sustainability. He joined Bureau Veritas in 1999 and has held leadership roles across the company. Juliano will continue to lead our corporate development and sustainability efforts in his current role as Executive Vice-President, Corporate Development & Sustainability. Article content Philipp Karmires Article content remains Executive Vice-President Chief Digital & Innovation Officer. He is a senior executive with over 20 years of experience in digital transformation, enterprise software and product innovation. Philipp joined Bureau Veritas in 2024 and will continue to lead the DxT (Digital & Technology) function as Executive Vice-President, Chief Digital & Innovation Officer. Article content François Chabas Article content remains Executive Vice-President Chief Financial Officer. He joined Bureau Veritas in 2003, holding finance roles with increasing responsibility before becoming Chief Financial Officer in 2014. François will continue to lead the finance function as Executive Vice-President, Finance. Article content Maria Lorente Fraguas Article content remains Article content Article content Executive Vice-President Chief People Officer. She joined Bureau Veritas in 2024 after holding senior operational and human resources roles in international companies across multiple countries. Maria will continue to lead the people function as Executive Vice-President, Chief People Officer. Article content Article content Executive Vice-President Legal & Internal Audit. She joined Bureau Veritas in 2020 after serving as general counsel for other companies in France. Béatrice will continue to lead the legal and compliance function as Executive Vice-President, Legal affairs & Internal Audit. Article content Article content Article content Article content Article content Contacts Article content ANALYST/INVESTOR CONTACTS Article content Article content Laurent Brunelle Article content Article content +33 (0)1 55 24 76 09 Article content Article content Article content Colin Verbrugghe Article content Article content +33 (0)1 55 24 77 80 Article content Article content Article content MEDIA Anette Rey Article content Article content +33 (0)6 69 79 84 88 Article content Article content Article content Martin Bovo Article content Article content +33 (0) 6 14 46 79 94 Article content Article content Article content Karine Ansart Article content Article content Article content Article content
Hans India
15-06-2025
- Automotive
- Hans India
Transport unions slam govt over ATS-based fitness tests
Rajamahendravaram: Leaders of the Transport Workers' Joint Action Committee (JAC) have accused the Andhra Pradesh government of imposing stringent new rules that are creating severe inconvenience to vehicle owners and drivers across the state. They particularly raised concerns over the privatised fitness (brake) tests being conducted at Automated Testing Stations (ATS), claiming these are causing damage to vehicle engines and escalating costs for transporters. Addressing a press conference on Saturday, JAC leaders including INTUC District President Vasamsetty Gangadhara Rao, former Deputy Mayor Bolisetti Satyanarayana Prasad, and Ambedkar Konaseema District President Vasamsetty Sattiraju, said that fitness tests, which were earlier conducted by Motor Vehicle Inspectors (MVIs) under the Transport Department, have now been handed over to private ATS centres, resulting in increased online challan fees and time wastage. Currently, the East Godavari district has only one ATS centre located in Rajanagaram. The leaders pointed out that the centre charges Rs 400 for heavy vehicles and Rs 200 for light vehicles as testing fees. Additionally, owners are required to pay Rs 1,320 for heavy vehicles and Rs 920 for light vehicles through online challans. Even after making these payments, vehicle owners are being forced to wait over six hours at the testing centre, with results taking up to a week to be released. Until then, vehicles cannot legally operate on roads, creating further disruptions. They criticised the state government for blindly implementing a system introduced by the Central government, noting that it has already faced opposition from transport unions in Gujarat, Rajasthan, and Karnataka. However, in Gujarat, vehicle owners are allowed to get their fitness tests done either at ATS centres or directly through MVIs an option the JAC wants replicated in Andhra Pradesh to safeguard the transport sector. The leaders announced that a peaceful protest would be organized on July 1 at the Rajanagaram ATS centre, demanding immediate policy revision. As part of this protest, a transport strike will be observed from 8 am to 2 pm on that day. They also warned of exposing corruption allegedly taking place in the ATS centres. Urging the ruling coalition government to reconsider the current fitness testing policy, the JAC demanded relief for lorry owners, small car operators, auto drivers, and minivan owners suffering due to the new system.
Associated Press
02-06-2025
- Business
- Associated Press
Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA
OXFORD, England and MASON, Ohio, June 2, 2025 /PRNewswire/ -- Following the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc to advance OCB's proprietary ToxNav® test in the USA. ToxNav® is a revolutionary precision oncology test that identifies patients most at risk of undergoing severe toxicity upon treatment with 5FU/capecitabine, which, in extreme cases, can lead to the patient's death. Mira Precision Health, headquartered at the Mason 5155 BioHub—a dynamic biology and technology center in Mason, Ohio, USA—is dedicated to advancing precision medicine by delivering innovative solutions that empower clinics, health systems, and independent providers to enhance patient care and streamline clinical workflows. OCB and Mira Precision will collaborate to advance ToxNav® in the United States, establishing a substantial future market and sales presence. Dr. David Kerr, Founder and Director of the Board of OCB, and Professor of Cancer Medicine at Oxford University, commented, 'We developed our ToxNav test to identify cancer patients that have a high likelihood of undergoing extreme toxicity to 5FU/capecitabine treatment, which is one of the most widely used cancer drugs in the world. We have already clinically proven that ToxNav identifies patients that are susceptible to extreme toxicity and are excited to have partnered the test with Mira Precision, who have complementary expertise to advance ToxNav in the USA. We look forward to a long and productive relationship with Mira Precision as we advance ToxNav to widen its clinical utility in the USA and save more patient lives.' Dr. Sandra Gunselman, Founder and CEO of Mira Precision Health, said, 'I founded Mira Precision Health with the vision of bringing the most innovative and personalized diagnostic solutions to healthcare providers and their patients. Our collaboration with Dr. Kerr and the renowned team at Oxford Cancer Biomarkers marks an exciting inflection point for Mira, allowing us to partner with globally-respected academic medical centers and deliver advanced precision medicine directly into clinical practice. Together, we're committed to significantly improving patient care and outcomes across the United States.' Karen Merritt, Co-Founder of Advocates for Universal DPD/DPYD Testing, comments, 'I strongly support the partnership between Oxford Cancer Biomarkers and Mira Precision Health, as it represents a critical step toward safer, more comprehensive pretreatment DPYD screening to prevent avoidable toxicity and save lives.' ToxNav® enhances clinical decision-making through comprehensive genetic profiling, aligning directly with recent NCCN Guidelines updates that recommend DPYD testing for colorectal cancer patients receiving fluoropyrimidine-based treatments. Shaun Peterson, VP of Sales and Marketing at Mira Precision Health, noted, 'The NCCN revision underscores the timely clinical importance of the Mira Precision ToxNav® Test in the US market. Backed by multiple peer-reviewed studies and CE-IVD certification in the UK, ToxNav® significantly improves patient outcomes, reduces healthcare costs, and advances equitable precision medicine. This partnership between Oxford Cancer Biomarkers and Mira Precision Health reinforces our commitment to personalized cancer care innovation.' Michele Blair, Director of Economic Development for the City of Mason, said, 'We are excited to partner with Mira Precision Health to further science partnerships like ToxNav. Using the Mason Living Lab we have been able to connect an educated population with new and growing health technology to achieve faster commercialization. The new Mira Precision ToxNav® Test is an excellent addition to our portfolio of technology.' About Oxford Cancer Biomarkers Ltd (OCB) Oxford Cancer Biomarkers (OCB) is a spin-out from the University of Oxford, developing and commercialising a suite of molecular and AI-enabled diagnostic tools that harness the analytical capabilities of pharmacogenomic markers and digital pathology to optimise cancer treatment pathways. OCB continues to expand its portfolio with novel biomarkers and proprietary algorithms that enable clinicians to make personalized treatment recommendations based on real-world evidence, empowering patients to make better-informed decisions about their own cancer therapy. Its most recent investment came from Plutus Investments Group LLP, which is a multi-family office backing entrepreneurs in Europe and the USA, focused on Life Sciences, Biotech, Fintech, and Tech investments. For more information, please visit About Mira Precision Health, Inc. Mira Precision Health was founded to provide advanced molecular diagnostic testing directly to healthcare providers and communities. Inspired by the empowerment and strength symbolized by the name 'Mira,' Founder and CEO Dr. Sandra J. Gunselman envisioned reshaping precision medicine by equipping clinics, health systems, and independent providers with cutting-edge clinical genomics, pharmacogenomics expertise, and data informatics tools. Mira Precision Health is dedicated to enhancing clinical decision support, improving patient safety, and delivering personalized, data-driven healthcare solutions that significantly elevate patient outcomes. For more information, please visit About The City of Mason BioHub Recognized as a leader in Ohio and the Midwest, the City of Mason BioHub is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. With $600 million in new investment and more than 1,200 jobs announced in 2024 primarily in this sector, the City's Economic Development arm has created an unmatched model for scaling young growth companies. Through its proprietary Living Lab initiative, the City is able to leverage its diverse demographic population and scientific business community to scale young HealthTech companies, while improving personal health outcomes for residents. For more information about the City of Mason, visit or For further information, please contact: Oxford Cancer Biomarkers Ltd Tel: 0044 7976 708535 Mira Precision Health, Shaun Peterson, Vice President, Sales and Marketing, [email protected] View original content to download multimedia: SOURCE City of Mason
